Spread the love

A recent study from the Glenn Laboratory for the Science of Aging and Department of Biology, Massachusetts Institute of Technology, Cambridge, United States of America shows that “Muscle-Specific Sirtuin-1 Gain-of-Function Increases Slow-Twitch Fibers and Ameliorates Pathophysiology in a Mouse Model of Duchenne Muscular Dystrophy.”

This study was published in the Jul 17 journal PLoS Genetics by Prof Guarente LChalkiadaki A and others the Glenn Laboratory for the Science of Aging and Department of Biology, Massachusetts Institute of Technology, Cambridge.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Antagomir-based therapy for Muscle degenerative disease: MiRNA-128 aggravates the Pathophysiology of Duchenne Muscular Dystrophy via down regulation of its target geneThis study suggests that miR-128, by decreasing the expression of its target gene, it may aggravate the Pathophysiology of Duchenne Muscular Dystrophy. Together, this study suggests that pharmacological formulations encompassing” Antagomir-128” may be used to treat Duchenne Muscular Dystrophy.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, L., Antagomir-based therapy for Muscle degenerative disease: MiRNA-142 aggravates the Pathophysiology of Duchenne Muscular Dystrophy via down regulation of its target gene, 30/July/2014, 8.53 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love